Pharm Country

Found 131,789 articles

• 

  BioSpace Launches 2022 Hotbed Maps to Highlight Thriving Life Sciences Clusters

  1/18/2022

  As BioSpace proudly introduces our 2022 Hotbed Maps, let’s explore the industry’s most thriving territories, research leading employers and search for relevant jobs on BioSpace.

• Agile Therapeutics Announces Pricing of $7.5 Million Public Offering

  5/23/2023

  Agile Therapeutics, Inc., a women's healthcare company, announced the pricing of its public offering of an aggregate of 1,896,286 shares of its common stock, together with accompanying common stock warrants, at a public offering price of $3.9551 per share and accompanying warrants.

• US FDA approves the Cyltezo® Pen, a new autoinjector option, ahead of July 1 commercial launch

  5/22/2023

  Boehringer Ingelheim announced today that the U.S. Food and Drug Administration (FDA) has approved the Cyltezo ® Pen, a new autoinjector option for Cyltezo (adalimumab-adbm), an FDA-approved Interchangeable biosimilar to Humira® (adalimumab). Initially approved as a pre-filled syringe, Cyltezo is indicated to treat multiple chronic inflammatory diseases.

• Yaral Pharma Partners With EVERSANA to Support the Commercialization of Its Expanding Generics Portfolio

  5/22/2023

  Yaral Pharma Inc. today announced its expanding partnership with EVERSANA ® , a leading provider of commercialization services to the global life sciences industry, as its key commercialization partner to support the expansion of its portfolio of pain and endocrinology products in the U.S.

• Siblings with autism share more of dad's genome, not mom's

  5/22/2023

  Scientists long thought that siblings born with ASD share more of their mother's genome than their father's.

• Trevi Therapeutics Announces Publication of Positive Data from the CANAL Trial in IPF Chronic Cough in NEJM Evidence

  5/22/2023

  Trevi Therapeutics, Inc. (Nasdaq: TRVI) today announced the positive results from the Phase 2 CANAL trial in adults with IPF chronic cough has been published in NEJM Evidence.

• Enzo Biochem Reports Significant Progress towards Completing the Clinical Lab Asset Sale

  5/22/2023

  Enzo Biochem, Inc., announced that the preliminary voting results from the Inspector of Election at today’s Special Meeting of the Shareholders indicate that the Asset Sale Proposal was approved by the affirmative vote of a majority of Enzo’s outstanding common stock.

• Quantum-Si Appoints Life Sciences and Diagnostics Industry Leader Jack Kenny to its Board of Directors

  5/22/2023

  Quantum-Si Incorporated today announced the appointment of Jack Kenny, CEO of Meridian Bioscience, Inc., to its Board of Directors.

• Avalo Announces Appointment of Michael Croft, Ph.D. and Jeff Edelson, M.D. to its Scientific Advisory Board

  5/22/2023

  Avalo Therapeutics, Inc. (Nasdaq: AVTX) announced the appointment of Dr. Michael Croft and Dr. Jeff Edelson to the company’s Scientific Advisory Board (SAB).

• Robert J. Coury to Transition from Executive Chairman of Viatris to Chairman Emeritus and Senior Strategic Advisor to the Board and Management at the End of the Year

  5/22/2023

  Viatris Inc. Robert J. Coury will once again transition his role, this time from his current position of Executive Chairman to Chairman Emeritus and Senior Strategic Advisor to the board and management following the company's 2023 annual meeting of shareholders.

• Bristol Myers Squibb’s Investigational LPA1 Antagonist Reduces the Rate of Lung Function Decline in Patients with Idiopathic Pulmonary Fibrosis

  5/22/2023

  Bristol Myers Squibb (NYSE: BMY) today announced results from a Phase 2 study evaluating BMS-986278, a potential first-in-class, oral, lysophosphatidic acid receptor 1 (LPA1) antagonist, in patients with idiopathic pulmonary fibrosis.

• Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2023

  5/22/2023

  Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today reported corporate updates and financial results for its fiscal fourth quarter and fiscal year ended March 31, 2023.

• Tonix Pharmaceuticals Announces Clinical Proof-of-Concept Study of TNX-1900 (Intranasal Potentiated Oxytocin)

  5/22/2023

  Tonix Pharmaceuticals Holding Corp. today announced that it has entered into a research collaboration agreement to evaluate the effect of TNX-1900 (intranasal potentiated oxytocin) on capsaicin- or electrical stimulation-induced forehead dermal blood flow in healthy female human volunteers.

• NeuBase Announces Positive Preclinical Data Supporting the Capabilities of Stealth Editors™

  5/22/2023

  NeuBase Therapeutics, Inc. today announced a broad set of preclinical safety and efficiency data for its Stealth Editors development program that demonstrate the ability to achieve gene editing with a non-immunogenic system.

• Krystal Biotech Announces $160 Million Private Placement Equity Financing

  5/22/2023

  Krystal Biotech, Inc. today announced that it has entered into a securities purchase agreement for the sale of 1,729,729 shares of its common stock at $92.50 per share in a private placement (the PIPE) to certain qualified institutional buyers.

• Cabaletta Bio Announces Closing of $100 Million Public Offering of Common Stock, Including Full Exercise of Option to Purchase Additional Shares

  5/22/2023

  Cabaletta Bio, Inc. announced the closing of an underwritten public offering of 8,337,500 shares of its common stock, including the exercise in full by the underwriters of their option to purchase an additional 1,087,500 shares, at the public offering price of $12.00 per share.

• Kelyniam Global Releases Q1 Financials, Announces Licensing Agreement with Bioplate for Osteopore Products

  5/22/2023

  Kelyniam Global, a leading maker of custom cranial implants, announced results for its quarter ended March 31, 2023.

• Precipio’s Lab Detects BCR-ABL1 Oncogene Co-Expression of p190 & p210 Isoforms in a CML Patient By Using HemeScreen® TechnologyPanel-Based Approach of Driver Mutation Detection Proves Crucial for Patient Care

  5/22/2023

  Specialty cancer diagnostics company Precipio, Inc. leveraged its proprietary HemeScreen technology as part of the diagnostic process to monitor a patient with a history of Chronic Myeloid Leukemia and p210 isoform expression which allowed the lab to uncover an additional oncogene isoform expression.

• Avantor® and Labguru Collaborate to Drive More Efficient Lab Buying Experience

  5/22/2023

  Avantor, Inc. has entered into an agreement with Labguru, a research-to-production platform of choice for leading global pharma, national research institutes and innovative startups, to integrate Avantor's Inventory Manager and e-commerce channel into Labguru's Lab Information Management Software (LIMS) and Electronic Lab Notebook (ELN).

• GeneDx Regains Compliance with Nasdaq Minimum Bid Price Requirement

  5/22/2023

  GeneDx announced that it had received a letter from The Nasdaq Stock Market LLC stating that, because the Company’s Class A common stock had a closing bid price at or above $1.00 per share for a minimum of ten consecutive business days, the Company had regained compliance with the minimum bid price requirement of $1.00 per share for continued listing on the Nasdaq Global Select Market, as set forth in Nasdaq Listing Rule 5450, and that the matter is now closed.